Regulatory FDA turns to old drugs to address new diseases, persistent medical needs BioSpaceThe FDA is looking to retool drugs with sufficient evidence to support their use in other indications, particularly those with unmet need.Read full story pharminent May 12, 2026 (Last updated: May 16, 2026) BioSpace The FDA is looking to retool drugs with sufficient evidence to support their use in other indications, particularly those with unmet need. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novo says high-dose Wegovy can cause 28% weight lossNext: BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
